Led by pioneers in synthetic biology and computation, Senti is pioneering new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies.

Milestones
  • 2016 Founded
  • 2018 Partnered, Series A
  • 2022 IPO; NASDAQ: SNTI
Partner
senti_bio_graphic